Xiaochu Man

Jinan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.

Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial.

Journal: Clinical and translational medicine

Published: January 24, 2024

Identification of significant single-nucleotide polymorphisms associated with breast cancer recurrence and metastasis using GWAS.

Identification of significant single-nucleotide polymorphisms associated with breast cancer recurrence and metastasis using GWAS.

Journal: Cancer innovation

Published: January 03, 2024

Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study.

Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study.

Journal: Clinical breast cancer

Published: August 08, 2023

The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages.

The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages.

Journal: Cancer medicine

Published: February 21, 2023

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer.

Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer.

Journal: Frontiers in genetics

Published: December 16, 2022

Survival analysis and nomogram for early-stage occult breast cancer with positive lymph nodes based on the SEER database.

Survival analysis and nomogram for early-stage occult breast cancer with positive lymph nodes based on the SEER database.

Journal: Annals of translational medicine

Published: October 20, 2022

Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.

Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study.

Journal: Cancer medicine

Published: October 23, 2021

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.

Journal: Frontiers in oncology

Published: September 19, 2021

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression.

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression.

Journal: Frontiers in oncology

Published: July 08, 2021

Showing 1-9 of 9

Last Updated: 09/26/2026